Reddy博士, Hetero在印度和120个低收入国家获得艾滋病毒治疗Lenacapavir免特许使用费许可证。 Dr. Reddy's, Hetero obtain royalty-free licensing for HIV treatment Lenacapavir in India and 120 low-income countries.

Reddy博士的实验室和赫特罗与Gilead Science公司签订了免特许使用费许可证协议,在印度和120个低收入和中低收入国家制造和分销艾滋病毒创新治疗Lenacapavir。 Dr. Reddy's Laboratories and Hetero have secured royalty-free licensing agreements with Gilead Sciences to manufacture and distribute Lenacapavir, an innovative HIV treatment, in India and 120 low- and lower-middle-income countries. 这一伙伴关系旨在增加获得这种美国FDA批准的药物的机会,该药物针对抗多种药物的艾滋病毒,并支持预防艾滋病毒的努力。 This partnership aims to enhance access to this USFDA-approved drug, which targets multi-drug-resistant HIV, and support HIV prevention efforts. 目标是改善服务不足的人口在疾病负担沉重时的治疗选择。 The goal is to improve treatment options for underserved populations facing high disease burdens.